保留血管吻合修复与横断吻合修复治疗孤立性短段球部尿道狭窄的随机对照试验
本研究为前瞻性、多中心、单盲、1:1随机对照非劣效性II期试验,计划纳入100例孤立性短段球部尿道狭窄患者,比较保留血管吻合修复(vsAR)与横断吻合修复(tAR)的无失败生存率,非劣效界值10%。主要终点为24个月随访无失败生存,失败定义为16-Fr软性膀胱镜无法通过重建区。
要点
- vsAR对比tAR治疗短段球部尿道狭窄,主要终点为24个月无失败生存率。
- 非劣效界值设为10%,样本量100例(每组50例)。
- 术后3、12、24个月随访,评估并发症与功能结局。
核心结论
- 正在进行的II期随机对照试验将评估vsAR是否在24个月无失败生存率上非劣效于tAR,非劣效界值10%。
研究设计与样本
- 前瞻性、干预性、多中心、单盲、1:1随机对照、非劣效性II期试验,计划样本量100例(每组50例)。
- 随机化由独立第三方使用计算机随机序列生成器,采用可变区组大小的置换区组。
关键数值与推荐
- 主要终点为24个月随访无失败生存率,非劣效界值10%。
- 失败定义为16-Fr软性膀胱镜无法通过重建区且不损伤尿道黏膜。
- 次要终点包括术后并发症差异和功能结局参数变化,采用经验证问卷评估。
临床怎么用
- 若证实非劣效,vsAR可能成为治疗孤立性短段球部尿道狭窄的创伤更小的替代术式。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Vessel-sparing anastomotic repair (vsAR) has been developed as a less traumatic alternative to transecting anastomotic repair (tAR) to treat isolated short bulbar urethral strictures. This vessel-sparing technique could result in improved functional outcomes without jeopardizing the excellent surgical outcome after (transecting) anastomotic repair. The purpose of this study is to directly compare vsAR and tAR for both surgical and functional outcomes. METHODS: This trial is a prospective, interventional, multi-center, single-blinded, 1:1 randomized, controlled, non-inferiority, phase II trial. Sample size calculation resulted in a required sample size of 100 patients (50 patients per arm). Trial participants will be randomized by an independent third party using a computer-based random sequence generator with permuted blocks of variable size. The primary objective of this trial is to show that vsAR is non-inferior to tAR in terms of failure-free survival after 24 months of follow-up, considering a non-inferiority limit of 10%. Failure is defined as the inability to pass a 16-Fr flexible cystoscope through the reconstructed area without damaging the urethral mucosa. Secondary end-points mainly include differences in postoperative complications and changes in functional outcome parameters, which will be assessed with validated questionnaires. All participants are scheduled for follow-up at 3, 12, and 24 months postoperatively. DISCUSSION: This trial will provide level Ib evidence about the differences in both surgical and functional outcome between vsAR and tAR, which may importantly scape the future of bulbar urethral reconstruction. Depending on the trial results, this phase II trial may generate a larger phase III trial with more statistical power and a lower alpha value. TRIAL REGISTRATION: This trial is registered at clinicaltrials.gov ( NCT03572348 ) and in the Belgian Clinical Trial Registry (B670201837335). The trial was registered prospectively. Registered on 28 June 2018.
引用
- Verla W, Waterloos M, Waterschoot M, et al. VeSpAR trial: a randomized controlled trial comparing vessel-sparing anastomotic repair and transecting anastomotic repair in isolated short bulbar urethral strictures. Trials. 2020. PMID: 32917251. doi:10.1186/s13063-020-04712-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。